Pierre Fabre launches a collaborative project in translational medicine to advance a proprietary antibody-drug conjugates (ADC) in oncology
June 28, 2016
Oncology is a priority for Pierre Fabre Pharmaceuticals R&D
This new collaboration stems from the open innovation’s strategy implemented by Pierre Fabre in 2015 with the objective to develop R&D partnerships worldwide
Castres (France), 28 June 2016 – Pierre Fabre Pharmaceuticals is announcing a research project in translational medicine on a proprietary drug target in oncology. The collaboration includes David L. Rimm, MD, PhD, Professor of Pathology at Yale School of Medicine and the Pierre Fabre Pharmaceuticals R&D Translational Medicine department headed by Dr. Alexandre Passioukov.
This collaboration focuses on a precision medicine approach to develop a first-in-class antibody-drug conjugate (ADC) identified by the Pierre Fabre Pharmaceuticals teams. Both partners will work on the translational aspects of the project to enable the progression of this drug candidate into clinical trial.
Yale University possesses a world-class oncology team that leverages cutting edge biomarker analysis technologies. Pierre Fabre Pharmaceuticals benefits from a recognized continuum between research, development and production of small molecules, monoclonal antibodies and antibodies drug conjugates (ADC).
We are delighted to be collaborating with Yale, a world class university and medical center. This international collaboration reinforces our R&D’s organization commitment to work with the best teams in our areas of strategic interest and will reinforce our ability to bring new oncology treatment to patients in the most effective manner» declared Laurent Audoly, Head of Research and Development Pierre Fabre Pharmaceuticals.
Press Contact :
Valérie Roucoules - 01 49 10 83 84